3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
AssigneeRenovis, Inc.
InventorsL. David Waterbury, Allan L. Wilcox, John M. Carney, Farah Mavandadi, Albert Danielzadeh
Life of this patent
Estimating the term…
Abstract
Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R1-R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.
Claims13
A method for treating a mammal with an inflammation-related condition selected from the group consisting of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and systemic lupus erythematosus which method comprises administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective inflammation-reducing amount of a compound of formula I:
- wherein
- R1 is selected from the group consisting of:
- each R2 is independently selected from a group of the formula:
- R3 is selected from the group consisting or hydrogen, alkyl, cycloalkyl and aryl;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;
- or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen, sulfur, —S(O)— or —S(O)2—;
- and
- W is oxygen or sulfur;
- and pharmaceutically-acceptable salts thereof.
A compound of formula I:
- wherein
- R1 is selected from the group consisting of:
- each R2 is independently selected from a group of the formula:
- R3 is hydrogen;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 is selected from the group consisting of alkyl and alkoxycarbonylalkyl;
- R7 is hydrogen;
- R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;
- or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen, sulfur, —S(O)— or —S(O)2—;
- and
- W is oxygen or sulfur;
- and pharmaceutically-acceptable salts thereof subject proviso that the compound is not α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.
A compound of formula I:
- wherein
- R1 is selected from the group consisting of:
- each R2 is independently selected from a group of the formula:
- R3 is hydrogen;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R8 is selected from the group consisting of alkyl and alkoxyalkyl;
- R9 is hydrogen;
- R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;
- or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen;
- and
- W is oxygen;
- and pharmaceutically-acceptable salts thereof subject to the proviso that the compound is not a α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula I:
- wherein
- R1 is selected from the group consisting of:
- each R2 is independently selected from a group of the formula:
- R3 is hydrogen;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 is selected from the group consisting of alkyl and alkoxycarbonylalkyl;
- R7 is hydrogen;
- R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;
- or R11 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen, sulfur, —S(O)— or —S(O)13 ;
- and
- W is oxygen or sulfur;
- and pharmaceutically-acceptable salts thereof to the proviso that the compound is not α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.
A pharmaceutically composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula I:
- wherein
- R1 is selected from the group consisting of:
- each R2 is independently selected from a group of the formula:
- R3 is hydrogen;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R8 is selected from the group consisting of alkyl and alkoxyalkyl;
- R9 is hydrogen;
- R10 is selected from the group consisting at hydrogen, lower alkyl and lower cycloalkyl;
- or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen;
- and
- W is oxygen;
- and pharmaceutically-acceptable salts thereof subject to the proviso that the compound is not α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.
Dependencies are inferred from the claim text.